SEC Form 4 · accession 0001197350-26-000009
Mirum Pharmaceuticals, Inc. · MIRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Bjerkholt
Officer — CHIEF FINANCIAL OFFICER
Period of report
Aug 11, 2026
Accepted (ET)
Aug 12, 2026 · 5:14 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001759425
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 11, 2026 | S | 6,001 | $99.9016 | D | 36,355 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.
- F2. The weighted average sale price for the transaction reported was $99.901633, and the range of prices were between $99.90 and $99.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3Includes 175 shares of common stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan.